Jenburkt Pharmaceuticals Ltd Financials
Company Logo

Jenburkt Pharmaceuticals Ltd Financial Statement

Jenburkt Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue33.94
Operating Expense23.25
Net Profit7.42
Net Profit Margin21.86
Earning Per Share16.80
EBIDTA10.55
Effective Tax Rate23.36

Jenburkt Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual141.97
Operating Expenses Annual108.85
Operating Profit Annual37.79
Interest Annual0.27
Depreciation2.34
Net Profit Annual25.98
Tax Annual9.20

Jenburkt Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning3.66
Cash Flow from Operations8.12
Cash Flow from Investing-0.58
Cash Flow from Financing-7.08
Cash Flow at the End4.13

Jenburkt Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)26.62
PBIT Margin (%)24.97
PBT Margin (%)-67.51
Net PROFIT Margin (%)18.30
Return On Networth / Equity (%)19.44
Return On Networth /Employed (%)25.67
Return On Assets (%)18.85
Total Debt / Equity (X)0.01
Asset Turnover Ratio (%)1.03

Jenburkt Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual10.36
Total Current Assets Annual109.73
Non Current Assets Annual55.37
Total Shareholders Funds Annual144.94
Total Assets Annual165.10

Jenburkt Pharmaceuticals Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 5, 2024, Jenburkt Pharmaceuticals Ltd has a market capitalization of 304.27 Cr. Value Research classifies it as a Small-Cap company.
Yes, Jenburkt Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.00.
In FY 2023 , Jenburkt Pharmaceuticals Ltd recorded a total revenue of approximately 141.97 Cr marking a significant milestone in the company's financial performance.
Jenburkt Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.1% and 0.1% annually, respectively..
Jenburkt Pharmaceuticals Ltd's current PE ratio is 11.71.
Jenburkt Pharmaceuticals Ltd's ROCE averaged 24.6% from the FY ending March 2022 to 2024, with a median of 24.0%. It peaked at 25.9% in March 2023, reflecting strong capital efficiency over the period..
Jenburkt Pharmaceuticals Ltd's latest EBIT is Rs. 35.45 Cr, surpassing the average EBIT of Rs. 32.99 Cr over the 5 years..